Momenta Pharmaceuticals, Inc. (NASDAQ : MNTA) today reported positive top-line data showing safety, tolerability and proof of mechanism for M281 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Momenta Pharmaceuticals (MNTA) PT Raised to $15 at Stifel Following Positive M281 MAD Data, EYLEA Biosimilar UnveilingJanuary 5, 2018 12:40 PM Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy VolunteersJanuary 5, 2018 8:00 AM